Screener
Jade Biosciences JBIO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 318,517 | 348,816 |
| Property and equipment, net | 157 | 170 |
| Operating lease right-of-use asset | 690 | 726 |
| Other assets | 69 | 69 |
| Total assets | $319,433 | $349,781 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | 3,979 | 2,151 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's deferred tax assets and other non-current assets?
- Jade Biosciences (JBIO) reported deferred tax assets and other non-current assets of $69K in Q1 2026.
- What is the long-term trend for Jade Biosciences's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Jade Biosciences's deferred tax assets and other non-current assets has grown at a 7.1% compound annual growth rate (CAGR), from $49K to $69K.
Ask your AI about Jade Biosciences's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude